125 results
8-K
EX-99.2
NMTRQ
9 Meters Biopharma, Inc.
7 Dec 20
9 Meters Biopharma, Inc. Announces Positive Topline Data for NM-002, a Proprietary Long-Acting GLP-1, in Phase 1b/2a Trial for Short Bowel Syndrome
7:37am
an excellent safety and tolerability profile -Plan to meet with FDA as soon as possible in the first quarter of 2021 to discuss next steps for clinical … Design 8 Screening 50 mg cohort n = 2 100 mg Cohort n = 2 50 mg Cohort n = 1 100 mg Cohort n = 2 Total n=9 7 Day Safety Assessment 150 mg Cohort n = 1
8-K
EX-99.2
NMTRQ
9 Meters Biopharma, Inc.
29 Nov 22
9 Meters Biopharma Announces Phase 3 Study of Vurolenatide
8:05am
degradation time for long half-life (>150 hours) Offers dosing convenience (Q2W) Demonstrates strong safety and tolerability profile ✓ ✓ ✓ ✓ 12
Vurolenatide … status or remnant anatomy Excellent safety and tolerability regardless of remnant anatomy Improved QoL due to lower administration burden and improved
8-K
EX-99.2
NMTRQ
9 Meters Biopharma, Inc.
23 Mar 21
A Champion in GI With A One Tract Mind Focused on Rare and Unmet Needs in Gastroenterology Corporate Presentation
9:15am
weaned off Onset of Action Within hours-to-days of dosing – Weeks to months (2 to 6 months) Safety Known target Transient side effects Active … molecule has over 15 patient years of use – REMS program; safety concerns include: – Acceleration of neoplastic growth – Intestinal obstruction – Biliary
8-K
EX-99.1
NMTRQ
9 Meters Biopharma, Inc.
7 Dec 20
9 Meters Biopharma, Inc. Announces Positive Topline Data for NM-002, a Proprietary Long-Acting GLP-1, in Phase 1b/2a Trial for Short Bowel Syndrome
7:37am
improvements in TSO volume and bowel movement frequency
-Twice-monthly fixed-dosing regimen exhibited an excellent safety and tolerability profile
-Plan … .
The Phase 1b/2a clinical trial was an open-label, two-dose study evaluating the safety and tolerability of three escalating fixed doses of NM-002
8-K
EX-99.1
hzisbcw89
30 Jun 22
9 Meters Biopharma Announces Positive Preliminary Results from Phase 2 Study of Vurolenatide in Short Bowel Syndrome
7:06am
8-K
EX-99.1
bbxbm4f5y07
27 May 20
Other Events
4:31pm
8-K
EX-99.3
0oz0n wm6gj
4 May 20
Completes concurrent financing of ~$22 million led by Orbimed Advisors, LLC
5:24pm
8-K
EX-99.1
tmcituh5azs3aw280
23 Mar 21
A Champion in GI With A One Tract Mind Focused on Rare and Unmet Needs in Gastroenterology Corporate Presentation
9:15am
8-K
EX-99.1
nuibvje
7 Dec 20
Other Events
7:40am
8-K
EX-99.2
cpsigg
26 Sep 22
9 Meters Biopharma Announces Positive Final Results from Phase 2 VIBRANT Study and Successful End-of-Phase 2 Meeting with FDA
4:08pm
8-K
EX-99.1
dtohoa653d 9uljp6
11 May 20
9 Meters Biopharma, Inc Receives Thorough QT Study Waiver by FDA for Larazotide Being Studied for Celiac Disease
4:36pm
8-K
EX-99.1
w029bo18z2r f1hu
15 Aug 22
9 Meters Biopharma Provides Business Update and Reports Financial Results for Second Quarter 2022
7:03am
8-K
EX-99.1
oj6ooi8tr9v7is6
29 Nov 22
9 Meters Biopharma Announces Phase 3 Study of Vurolenatide
8:05am
8-K
EX-99.1
4qczm7wp6huj
14 Jun 21
9 Meters Announces Initiation of Phase 2 VIBRANT Study of Vurolenatide for Short Bowel Syndrome
7:32am
8-K
EX-99.1
85imgv3 loxtojw
21 Dec 20
Other Events
7:33am